Lilly Q3 revenue up 18% to $6.77B; non-GAAP EPS $1.94 (+38%); pipeline advances with tirzepatide, donanemab

ELI LILLY & Co

2021-Q3 EPS reported $4.23 revenue$20,318,500,000

Q3 revenue $6.773B (+18% YoY); GAAP EPS $1.22 (-8%), non-GAAP EPS $1.94 (+38%).
Key growth products (Trulicity +45%, Verzenio +43%) drove 17pp of growth; COVID-19 antibody revenue $423.5M.
Submitted tirzepatide NDA for type 2 diabetes with priority review voucher; initiated rolling submission for donanemab in early Alzheimer's.
FDA approved Verzenio for high-risk early breast cancer and Jardiance for HFrEF; positive Phase 3 for lebrikizumab in atopic dermatitis.
Repurchased higher-cost debt ($405.2M charge); issued €600M sustainability bond.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.